FOLH1 and prostate cancer: Radioactive actinium (225Ac)– or lutetium (177Lu)–labeled prostate-specific membrane antigen (PSMA)–617 are low molecular weight ligands of prostate-specific membrane antigen and are used in the treatment of prostate cancer.